ATCC Announces Award from NIAID to Develop Research Capabilities in Infectious, Immunologic, and Allergic Diseases
ATCC announced that it has been awarded a seven-year contract by NIAID to develop research capabilities in infectious, immunologic, and allergic diseases.
ATCC has hired Greg Ballish as its new chief commercial officer. In this role, Ballish will lead ATCC’s sales and marketing operations and help oversee the corporate business and commercial center.
The ATCC Board of Directors added Melissa Rewolinski, Steve Curts, and Heather Kiessling to advise senior leadership on a variety of business, strategy and science-related issues.
ATCC announces the promotion of Dr. Joseph Leonelli to senior vice president of ATCC Federal Solutions.
ATCC announced that it has made two key appointments within its leadership team.
ATCC is expanding its collection of 2-D and 3-D patient tissue-derived in vitro cancer models, including organoids, as part of the Human Cancer Models Initiative to help scientists study cancer and identify and target novel therapies.
ATCC announced that five high-quality, concentrated virus preparations that it produced and stored under contract from the FDA/CBER have been designated as international reference reagents for high-throughput sequencing technologies by the World Health Organization.
ATCC announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program.